Chasing Lilly and Pfizer, Concert's JAK inhibitor hits high notes in phase 3 alopecia trial

Concert Pharmaceuticals has hit the high notes in a phase 3 alopecia areata clinical trial, finding 41.5% of people had at least 80% scalp hair coverage after taking the high dose of its JAK inhibitor. The data put Concert in the wings as Eli Lilly and Pfizer prepare to take to the stage and compete for the market.